FDA extends review time for weekly Novo Nordisk insulin
It will take three months longer for the FDA to review Novo Nordisk’s marketing application for icodec, a type of insulin administered weekly, than first thought, Novo Nordisk states in its 2023 report.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.